Novel Antipsychotics: Ulotaront (TAAR1 Agonis...

Apologies for our little hiatus - a couple of us had cross-country moves in June. But we're back! Today we have an episode on the rising use of recreational Kratom and pertinent tidbits to know from a psychiatry standpoint. References: https://pmc.ncbi.nlm.nih.gov/articles/PMC8924 ...  Show more

Welcome back! Today, we are looking at Modafinil and it's nuanced use in psychiatry.References:Provigil (modafinil) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc. U.S. Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfd ...  Show more

A new medication for psychosis is on the horizon. It's called KarXT and it could mean fewer side effects as well as finally some relief from difficulties with attention, concentration and memory - these are the symptoms patients often report as having the greatest impact on their ...  Show more

In this episode, we review the high-yield topic of Antipsychotics from the Psychiatry section.

Follow Medbullets on social media:

Facebook: www ...

We begin with a discussion about our article of the week which comes from The Lancet and is entitled “Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-c ...

Send us Fan MailDoes using cannabis put you at a greater risk of developing schizophrenia? Is it safe to use psychedelic-assisted therapy for psychotic disorders? Is there a difference between the psychotic experience and the psychedelic experience?In today’s episode of the Psych ...  Show more